

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/733,306
		Filing Date	December 8, 2000
		First Named Inventor	Margaret A. Schwarz
		Group Art Unit	1633
Examiner Name	Janet L. Epps Ford		
Sheet	1	of	1
		Attorney Docket Number	9022-20

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No..	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code, Number, Kind Code (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	SCHLUESENER HJ et al. Localization of endothelial-monocyte-activating polypeptide II (EMAP II), a novel proinflammatory cytokine, to lesions of experimental autoimmune encephalomyelitis, neuritis and uveitis: expression by monocytes and activated microglial cells. <i>Glia</i> . (1997) 20:365-372.	
	2.	KNIES UE et al. Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. <i>Proc. Natl. Acad. Sci. USA</i> . (October 1998) 95:12322-12327.	
	3.	SCHWARZ MA et al. Angiogenesis and morphogenesis of murine fetal distal lung in an allograft model. <i>Am J Physiol Lung Cell Mol Physiol</i> . (2000) 278:L1000-L1007.	
	4.	ZHANG F and SCHWARZ MA. Temporo-spatial distribution of endothelial-monocyte activating polypeptide II, an anti-angiogenic protein, in the mouse embryo. <i>Developmental Dynamics</i> . (2000) 218:490-498.	
	5.	ZHU Z et al. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. (2002) 2(2):135-156.	
	6.	MURRAY JC et al. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis. <i>Journal of Leukocyte Biology</i> . (May 2004) 75:772-776.	
	7.	QUINTOS-ALAGHEBAND ML et al. Potential role for antiangiogenic proteins in the evolution of bronchopulmonary dysplasia. <i>Antioxidant & Redox Signaling</i> . (November 1, 2004) 6(1):137-145.	
	8.	SCHWARZ MA et al. Epithelial-mesenchymal interactions are linked to neovascularization. <i>Am. J. respire. Cell Mol. Biol</i> . (2004) 30:784-792.	
	9.	ZOHLNHÖFER D et al. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. <i>Molecular Pharmacology</i> . (2004) 65(4):880-889.	
	10.	NÜHRENBURG TG et al. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. <i>Cardiovascular Research</i> . (2008) 77:580-589.	

iDoc# 671841

Examiner Signature	/Phuong Huynh/	Date Considered	07/11/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.